| | Webinar: Signaling Pathway CDx for Therapy Response Prediction Wednesday, May 26, 2021 | 11am ET / 8am PT Learn how Philips and Qiagen are using mRNA technology in OncoSignal tests to quantify functional activity of disease-relevant signal transduction pathways in any cell and tissue type. This webinar will explore applications for both preclinical disease modeling and clinical measurement of response to targeted therapies and immunotherapies. Register Now. |
Pfizer eyes $26B in COVID-19 vaccine sales for the year, with $3.5B already in the bag Lilly takes variant-busting COVID-19 antibody into the clinic Lynch: COVID vaccines bringing new customers to CVS stores BioNTech, with partner Pfizer, on track to make 3B COVID vaccine doses in 2021, CEO says Moderna plans major expansion at Massachusetts manufacturing site to help boost COVID-19 vaccine supply UPDATED Coronavirus tracker: Pandemic may have led to decrease in mental healthcare, Anthem study finds COVID-19 tracker: Biden admin shakes up vaccination strategy; CureVac chief criticizes U.S. export controls Coworker, institutional support helped nurses maintain mental wellbeing during COVID-19 pandemic: survey Beckman Coulter targets midsized diagnostic labs with automated sample prep hardware launch Featured Story | By Fraiser Kansteiner Pfizer said its COVID-19 vaccine generated $3.5 billion in the first quarter, but that's nothing compared to what the drug giant expects for the full year. By the time 2021 is through, the company could see $26 billion in Comirnaty revenues, Pfizer predicts. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Eli Lilly has begun clinical development of an anti-SARS-CoV-2 antibody designed to work against all currently known circulating variants of concern. The action comes weeks after the FDA revoked the single use emergency authorization of Lilly’s first COVID-19 antibody due to the rise of variants. read more By Paige Minemyer CVS Health is raising its guidance for the year after posting $2.2 billion in profit for the first quarter. read more By Noah Higgins-Dunn BioNTech and U.S. partner Pfizer will be able to produce nearly 3 billion doses in 2021, higher than a previously estimated 2.5 billion doses, BioNTech CEO Ugur Sahin told the Financial Times. read more By Noah Higgins-Dunn Moderna will more than double the size of its manufacturing site in Norwood, Massachusetts, to help reach its newly elevated COVID-19 vaccine supply forecasts. The latest renovations will boost the facility's vaccine production by 50%, the biotech said. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Faced with a slowing vaccine rollout in some parts of the country, the Biden administration said it will shake up its distribution plan while also setting a new goal: 70% of Americans inoculated, even partially, by July 4. CureVac's CEO criticized the U.S. for controlling exports of necessary vaccine manufacturing supplies. And more headlines. read more By Dave Muoio Hospitals can play a major role in supporting workforce wellbeing by supplying adequate resources and training during a crisis, according to a survey of nearly 2,500 NYU Langone nurses. read more By Conor Hale The company’s new DxA 5000 Fit aims to automate the work performed in medium-sized labs, which run between about 2,000 and 5,000 tests per day by reducing up to 80% of the mundane steps. read more |
